Iovance Biotherapeutics To Present Clinical And Pre-Clinical Data For Tumor Infiltrating Lymphocyte Therapies At Society For Tumor Immunotherapy Of Cancer's 38th Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) will present clinical data and trial design for tumor infiltrating lymphocyte (TIL) therapies at the Society for Immunotherapy of Cancer's 38th Annual Meeting. The presentations will include a 4-year analysis of the C-144-01 study, a study on TIL with inducible and membrane-bound IL-12, and a phase 3 study of lifileucel TIL cell therapy combined with pembrolizumab.

September 27, 2023 | 8:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Iovance Biotherapeutics will present significant clinical data and trial design for its TIL therapies at a major conference. This could potentially impact the company's stock positively if the data presented is promising.
Presenting clinical data at a major conference is a significant event for a biotech company like Iovance Biotherapeutics. If the data presented is promising, it could lead to increased investor confidence and a potential rise in the company's stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100